Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms
Biological heterogeneity is a key feature of malignancies that significantly contributes to disease progression and therapy resistance. Residual/relapsed tumor foci may represent genetically divergent subclones, which remain uncovered as repeated and multiple tumor sampling is usually limited. The a...
Main Authors: | Emese Sarolta Bádon, Attila Mokánszki, Anikó Mónus, Csilla András, Gábor Méhes |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | Molecular and Cellular Probes |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0890850822001025 |
Similar Items
-
Quadruplicate Synchronous Adenocarcinoma of the Colon with Distant Metastases—Long-Term Molecular Follow-Up by KRAS and TP53 Mutational Profiling
by: Emese Sarolta Bádon, et al.
Published: (2020-06-01) -
Carbonic Anhydrase IX Expression and Treatment Response Measured in Rectal Adenocarcinoma Following Neoadjuvant Chemo-Radiotherapy
by: Emese Sarolta Bádon, et al.
Published: (2023-01-01) -
High Genetic Diversity and No Evidence of Clonal Relation in Synchronous Thyroid Carcinomas Associated with Hashimoto’s Thyroiditis: A Next-Generation Sequencing Analysis
by: Csaba Molnár, et al.
Published: (2020-01-01) -
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01) -
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
by: Giorgia Nardo, et al.
Published: (2021-01-01)